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The Ontario Brain Institute’s “Brain-CODE” is a large-scale informatics platform designed
to support the collection, storage and integration of diverse types of data across several
brain disorders as a means to understand underlying causes of brain dysfunction and
developing novel approaches to treatment. By providing access to aggregated datasets
on participants with and without different brain disorders, Brain-CODE will facilitate
analyses both within and across diseases and cover multiple brain disorders and a wide
array of data, including clinical, neuroimaging, and molecular. To help achieve these
goals, consensus methodology was used to identify a set of core demographic and
clinical variables that should be routinely collected across all participating programs.
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Establishment of Common Data Elements within Brain-CODE is critical to enable a
high degree of consistency in data collection across studies and thus optimize the
ability of investigators to analyze pooled participant-level data within and across brain
disorders. Results are also presented using selected common data elements pooled
across three studies to better understand psychiatric comorbidity in neurological disease
(Alzheimer’s disease/amnesic mild cognitive impairment, amyotrophic lateral sclerosis,
cerebrovascular disease, frontotemporal dementia, and Parkinson’s disease).
Keywords: common data elements, psychiatric comorbidity, major depressive disorder, neurological disorders,
data sharing, pooled participant data, depression and anxiety, brain-code

SELECTION OF CDEs

INTRODUCTION

Delphi Consensus Process

The Ontario Brain Institute’s (OBI) “Brain-CODE” informatics
platform (www.braincode.ca) (1) was designed to support the
collection, integration, sharing, and analysis of diverse types
of patient-level data across several brain disorders, including
neurodevelopmental disorders (www.pond-network.ca), cerebral
palsy (www.cpnet.canchild.ca), epilepsy (www.eplink.ca), major
depressive disorder (MDD, www.canbind.ca), concussion
(www.connectontario.ca), and neurodegenerative/neurovascular
cognitive disorders (www.ondri.ca). These programs provide
an opportunity to facilitate collaboration across disorders;
with pooling of data across these programs expanding the
utility of the individual datasets to support cross-disease
comparisons and generalizability of findings. However,
combining participant-level data from multiple studies and
patient populations can be challenging, as different measures
are often used to assess the same constructs (2). These data
must be sufficiently comparable to allow meaningful data
integration, and in the absence of common demographic
variables and outcome measures it is difficult to pool data
from different initiatives (2). Establishment up front of a
minimum set of unambiguously defined and standardized
assessments across initiatives will facilitate data sharing
and integration and enable meaningful cross-initiative
analyses (3–6).
To help achieve this level of collaboration and data
interoperability, a set of common demographic and clinical
outcome measures were identified and adopted across all
of the aforementioned research programs. The adoption of
common data elements (CDEs) within these studies reduces
the variability of data collection, and ultimately supports
the secondary use of Brain-CODE data by facilitating the
pooling of participant-level data across datasets (1, 3–6). The
primary objective of the present study was to use the CDEs
to assess psychiatric comorbidity across various neurological
diseases. We present here a summary of how we determined
and used the Brain-CODE CDEs, including an example using
CDEs pooled across three programs to assess symptoms of
depression and anxiety across neurological diseases (Alzheimer’s
disease/amnesic mild cognitive impairment, amyotrophic
lateral sclerosis, cerebrovascular disease, frontotemporal
dementia and Parkinson’s disease), as well as major depressive
disorder (MDD).

Frontiers in Psychiatry | www.frontiersin.org

A modified Delphi survey process (7, 8) was used to identify
core demographic and clinical variables to be collected across
all participating programs. Researchers from the five programs
were invited to an online survey hosted through the BrainCODE portal. Participants were asked to comment and respond
to statements on a 5-point Likert scale regarding the collection
of demographic and clinical variables, with possible responses
ranging from Not Important to Very Important (example: How
important is the collection of date of birth to achieving BrainCODE goals?) to Do Not Recommend to Highly Recommend
(example: Please provide your recommendation for the GAD7 to assess anxiety in adults across all programs) or Disagree
to Strongly Agree (example: QIDS-SR is appropriate to assess
depression across all programs in adults). A Do Not Know
option was included for all questions. Participants were also
provided open-ended questions to allow them to comment on
their answers, provide an additional opinion about Brain-CODE
CDEs beyond the specified variables, and whether additional
CDEs should be considered. The results were reviewed, and
anonymized aggregated ratings and comments were presented
back to the participants in a follow-up survey to obtain additional
opinion and clarification, as required. Participants were directed
to consider the results of the previous survey in their responses.
Prior to sending out the Delphi surveys, we identified
the demographic and clinical domains that would be brought
forward for consensus. Following the review of research project
data dictionaries, study protocols, and through interactions with
program researchers, we identified the following demographic
domains of relevance across programs to consider for consensus:
Sex, Date of Birth, Handedness, Ethnicity, Race, Education Level,
Marital Status, Primary Language, Place of Birth, Geographic
Region, and Height/Weight.
For the clinical CDEs, a preliminary online survey was sent
to the programs to provide opinions on the symptom domains
that may be of relevance to their program and across a broad
range of patient populations. The results were presented at
a follow-up workshop. Following group discussion there was
agreement that psychiatric and medical comorbidity, depression,
anxiety, sleep, quality of life, and activities of daily living should
be assessed across all programs. These domains were considered
relevant across programs, as comorbid psychiatric symptoms are
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often reported across a broad range of patient population that
can impact health (9–12). There was also agreement that when
possible, the measure should be patient-reported, brief and easy
to administer, widely used and validated, and available in the
public domain. Based on literature and expert opinion, potential
rating scales were then identified for each of the symptom
domains to consider for consensus. A summary of the scales
was presented to the participants in the Delphi survey with the
aim of achieving consensus for a common measure for each
symptom domain.
Although the threshold for consensus is arbitrary,
recommended criteria for Delphi consensus generally range from
70 to 80% of agreement within two categories (8). In the present
surveys, this would include ratings of Important/Very Important,
Recommend/Highly Recommend or Agree/Strongly Agree.
Consensus levels of >70% were considered, with other factors
also weighted including harmonization with existing relevant
databases. When consensus was not achieved, representatives
of the relevant programs were asked to discuss internally
and provide their recommendations. Thirty-six researchers
participated in the demographic surveys and 44 in the clinical
surveys. There was broad representation of opinion, including
Principal Investigators (27%), Co-Principal Investigators
(36%), Project Managers (27%), and Research Coordinators
and Investigators (9%). The respondents indicated that the
populations studied in their programs included adult (59%),
child and adolescent (46%), infant (18%), and geriatric (18%).

TABLE 1 | Brain-CODE demographic and clinical CDEs.
SUB-DOMAIN

Brain-CODE CDE

Patient

Demographic

Sex, date of birth, and handedness

characteristics

Socioeconomic status
(SES)

Ethnicity, marital status, occupation,
and household income

Physical and

Quality of life

WHO-QoL-BREF (adult)

Activities of daily living

Sheehan disability scale (adult)

mental health

Clinical

KINDL-R (child and adolescent)
Medical comorbidity

NINDS medical history

Psychiatric comorbidity

BSI (adolescent and adult)

Depression

QIDS-SR (adolescent and adult)

endpoints

RCADS (child and adolescent)
Anxiety

GAD-7 (adolescent and adult)
RCADS (child and adolescent)

Sleep

PSQI (adult)
CSHQ (adolescent and adult)

Method
Study Population and Datasets
Ontario Neurodegenerative Disease Research Initiative
The Ontario Neurodegenerative Disease Research Initiative
(ONDRI, NCT04104373) is a multi-site prospective cohort
study developed to characterize and track progression
of neurodegenerative and cerebrovascular disorders (16).
Cohorts include: Alzheimer’s disease (AD) or amnestic
single or multidomain mild cognitive impairment (MCI),
amyotrophic lateral sclerosis (ALS), cerebrovascular disease
(CVD), frontotemporal dementia (FTD), and Parkinson’s disease
(PD). These groups were included in the present study to
assess the impact of depression and anxiety across neurological
disorders. Please see Farhan et al. (16) and Sunderland et al. (17)
for protocol details, inclusion, and exclusion criteria.

Demographic and Clinical CDEs Selected
The demographic and clinical CDEs that were agreed upon are
shown Table 1 and are summarized in Supplementary Material.
To promote uptake and standardization of the CDEs, data
dictionaries for the CDEs were made available on the
Brain-CODE portal and electronic case report forms were
independently validated prior to data collection to ensure
adherence to naming standards. These core Demographic
and Clinical CDEs have been successfully implemented across
participating programs (please see www.braincode.ca for most
recent numbers of CDEs collected within each program).

Canadian Biomarker Integration Network for
Depression Study
The Canadian Biomarker Integration Network in Depression
Study (CAN-BIND-1, NCT01655706) is a prospective multisite study developed to identify biomarkers of antidepressant
response in MDD (18, 19). The study collects imaging, clinical,
and ‘omics data that will be used to build predictive models
of treatment response. Cohorts include people with MDD and
healthy comparison participants, both of which are included in
the present analysis. Please see Lam et al. (19) for protocol details,
inclusion, and exclusion criteria.

ASSESSMENT OF PSYCHIATRIC
COMORBIDITY ACROSS NEUROLOGICAL
DISEASES AND CONTROLS
Comorbid psychiatric symptoms are often reported across
a broad range of patient populations that can impact health
(9–12) and are an integral part of neurological disorders (13–
15). To better understand the expression of depression and
anxiety in neurological disorders, we analyzed Brain-CODE
CDEs (Demographics, QIDS-SR, and GAD-7) pooled across
the five neurological diseases (Alzheimer’s disease/amnesic
mild cognitive impairment, amyotrophic lateral sclerosis,
cerebrovascular disease, frontotemporal dementia, and
Parkinson’s disease) and MDD.

Frontiers in Psychiatry | www.frontiersin.org

DOMAIN

Brain-Eye Amyloid Memory Study
Brain-Eye Amyloid Memory Study (BEAM, NCT02524405) is a
multi-site investigational study of non-invasive ocular measures
in neurodegenerative disease. Cohorts include: AD/MCI, CVD,
PD, and Lewy body disease and healthy comparison participants.
Please see www.clinicaltrials.gov/ct2/show/NCT02524405 for
protocol details. Only healthy comparison participants were
included in the present analyses. In addition, although not
part of the BEAM inclusion criteria, only healthy comparison
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participants within normal limits on both the Montreal Cognitive
Assessment (Total Score ≥ 26) and the Toronto Cognitive
Assessment (Sum Index score > 281) were included in the
present analysis.

TABLE 2 | Internal consistency.
AD/MCI

ALS

CVD

FTD

PD

MDD

0.69

0.70

0.70

0.74

0.74

0.68

QIDS-SR
Cronbach’s alpha

Analysis Dataset

Item-total

All data from ONDRI, CAN-BIND, and BEAM were collected
and deposited into the Brain-CODE database (1). The illustrative
analysis dataset used in the present analysis included BrainCODE CDE data (Demographics, QIDS-SR, GAD-7, and WHOQoL BREF) collected at baseline in participants enrolled in
ONDRI (AD/MCI, n = 126; ALS, n = 40; CVD, n = 161; FTD,
n = 53; PD, n = 140), CAN-BIND (MDD, n = 211; Healthy
controls, n = 112), and BEAM (Healthy controls, n = 45).
The following cohorts were included in analyses:
AD/MCI (ONDRI),
ALS (ONDRI),
CVD (ONDRI),
FTD (ONDRI),
PD (ONDRI),
MDD (CAN-BIND),
CAN-BIND healthy controls, and
BEAM health controls.
All studies were carried out in accordance with the Declaration of
Helsinki and the International Council for Harmonization (ICH)
of Technical Requirements for Pharmaceuticals for Human Use
guidelines, and the study designs and procedures were reviewed
by the appropriate ethics committees; informed consent was
obtained from participants after full explanation of the nature of
the procedures.

Sleep

0.20

0.33

0.16

0.18

0.22

0.31

Sadness

0.50

0.46

0.31

0.33

0.51

0.52

Appetite

0.19

0.53

0.35

0.56

0.26

0.30

Concentration

0.45

0.24

0.51

0.32

0.56

0.46

Self-perception

0.44

0.26

0.35

0.31

0.45

0.36

Interest

0.45

0.52

0.55

0.60

0.59

0.43

Energy

0.50

0.49

0.54

0.50

0.50

0.46

Psychomotor

0.54

0.30

0.60

0.71

0.53

0.22

0.88

0.85

0.89

0.83

0.92

0.84

Nervous

0.65

0.70

0.78

0.78

0.78

0.66

Worry-stop

0.75

0.70

0.79

0.66

0.83

0.77

Worry too much

0.81

0.80

0.76

0.67

0.84

0.72

Relaxing

0.77

0.59

0.75

0.62

0.81

0.61

Restless

0.63

0.34

0.56

0.47

0.66

0.49

Annoyed

0.46

0.61

0.59

0.71

0.58

0.35

Afraid

0.65

0.67

0.56

0.21

0.74

0.54

GAD-7
Cronbach’s alpha
Item-total

Analyses
Demographic and clinical characteristics were calculated and
compared across all cohorts; ANOVA was used for comparison
of continuous variables and chi-squared for comparison of
categorical variables. Analyses were performed using SPSS V26.
A level of p < 0.05 was regarded as statistically significant.
Furthermore, to assess the validity of the CDEs in assessing
depression and anxiety across the different cohorts, Cronbach’s
alpha and item-total correlations were also calculated for the
QIDS-SR and GAD-7 within each of the cohorts as a measure
of the scale’s internal consistency.

Study Assessments
Symptoms of Depression
The QIDS-SR is a 16-item self-report measure that assesses the
severity of depressive symptoms based on DSM-5 criteria for a
major depressive episode, with items scored on a 4-point scale
from 0 to 3 (20). Scoring of the QIDS-SR converts the 16 items
into 9 DSM domains (sad mood, concentration, self-criticism,
suicidal ideation, interest, energy/fatigue, sleep disturbances,
and changes in appetite/weight), with the total score ranging
from 0 to 27. It is important to note that because of ethics
concerns (challenges in providing immediate follow-up with
those expressing suicidal ideation), item #12 assessing suicidality
was omitted from the QIDS-SR in both ONDRI and BEAM, and
was therefore removed from all analyses. This was not expected to
impact the scale’s ability to discriminate MDD, given that removal
of suicidality in other scales [for example, PHQ-9 (with suicide
item) vs. PHQ-8 (without suicide item)] does not impact the
scale’s psychometric properties (21).

Results
QIDS-SR and GAD-7 Internal Consistency
Table 2 shows Cronbach’s alpha and item-total correlations for
the QIDS-SR and GAD-7 for the ONDRI neurological disease
(ND) and CAN-BIND MDD cohorts. For the QIDS-SR, alphas
ranged from 0.68 (MDD) to 0.74 (FTD, PD), suggesting that
although some of the items are assessing the same construct,
and others may not. Notably, low item-total correlations (r <
0.3) were noted for the “Sleep” domain in AD/MCI, CVD, FTD,
and PD, which were also questionable within the ALS (r = 0.33)
and MDD (r = 0.31) cohorts. Other items identified as having
low item-total correlations, included “Appetite” in AD/MCI (r
= 0.19), PD (r = 0.26), which were also questionable in CVD
(r = 0.35) and MDD (r = 0.30); “Concentration” in ALS (r =
0.24); and FTD (r = 0.32); Self-perception in ALS (r = 0.26),
CVD (r = 0.35), FTD (r = 0.31). Low item-total correlations

Symptoms of Anxiety
The GAD-7 is a 7-item self-report measure that is used to assess
the severity of generalized anxiety symptoms (22). Items rate the
severity of the 7 symptoms over the past 2 week on a 4-point scale
(0 = not at all, 1 = several days, 2 = more than half the days, and
3 = nearly every day), with total score ranging from 0 to 21.

Frontiers in Psychiatry | www.frontiersin.org
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TABLE 3 | Demographic and clinical characteristics.
Cohort

AD/MCI

ALS

CVD

FTD

PD

MDD

Control (MDD)

Control (ND)

Program

ONDRI

ONDRI

ONDRI

ONDRI

ONDRI

CAN-BIND

CAN-BIND

BEAM

N
Age, years ± SD
Sex, % female

126

40

161

53

140

211

112

45

71.00 ± 8.16

62.00 ± 8.75

69.17 ± 7.41

67.89 ± 7.05

67.92 ± 6.38

35.30 ± 12.65

33.04 ± 10.74

66.73 ± 6.04

45.2%

40.0%

31.7%

35.8%

22.1%

63.0%

63.4%

75.6%

Education, years ± SD

15.09 ± 2.91

13.95 ± 2.44

14.37 ± 2.85

13.66 ± 2.61

15.31 ± 2.62

14.10 ± 2.07

15.65 ± 2.25

16.31 ± 2.03

QIDS-SR total ± SD

3.93 ± 3.12

6.28 ± 3.70*

4.27 ± 3.11

5.36 ± 4.07*

5.61 ± 3.28*

14.92 ± 3.76*

2.27 ± 1.94

3.04 ± 2.11

GAD-7 total ± SD

2.30 ± 3.60

3.30 ± 4.21

2.58 ± 3.90

2.72 ± 3.71

3.24 ± 4.11

11.79 ± 5.02*

0.89 ± 1.73

1.04 ± 1.82

*Significantly different than controls (p < 0.05).

Figure 1 shows the percentage of participants showing different
levels of depressive severity acorss cohorts. In the ALS, FTD, and
PD cohorts, at least mild symptoms of depression (total score >
5) were reported by 55, 35.7, and 43.5% of participants, and least
moderate symptoms of depression were reported by 15, 11.3, and
8.6% of participants, respectively. By contrast, mild or moderate
levels of depression or greater were reported by 2.2 and 0% of
BEAM healthy control participants, respectively (see Figure 1).
Differences were noted in total GAD-7 scores across cohorts
[F (7,886) = 137.77, p < 0.01]. As expected, the MDD cohort had a
significantly higher GAD-7 total score (11.79 ± 5.02) than CANBIND healthy controls (0.89 ± 1.73) and all ONDRI ND cohorts
(2.30 ± 3.60 to 3.30 ± 4.21) (all p < 0.05). GAD-7 total score
for the ONDRI ND cohorts, however, did not differ from BEAM
healthy controls (1.04 ± 1.82; see Table 3).

were also noted for the “psychomotor” item in ALS (r = 0.30)
and MDD (r = 0.22).
For the GAD-7, alpha was good across all cohorts, ranging
from 0.83 (FTD) to 0.92 (PD). Item-total correlations were also
acceptable (r > 0.3), which the exception of the GAD-7 “afraid”
item in FTD (r = 0.21; see Table 2).

Participant Demographic and Clinical Characteristics
Table 3 summarizes demographic and clinical characteristics of
the ND cohorts (AD/MCI, ALS, CVD, FTD, and PD), MDD
cohort and MDD- and ND-matched healthy controls. ANOVA
revealed significant age differences across cohorts [F (7,888) =
394.77, p < 0.01]. No age differences were found between
ONDRI ND cohorts and BEAM healthy controls or between
CAN-BIND MDD and healthy controls. As expected, the ND
cohorts were older than the MDD cohorts (see Table 3). Sex
differences were noted across cohorts, with the proportion of
female participants in the CAN-BIND cohorts representative
of the sex distribution of MDD (10, 23, 24). The ONDRI
ND cohorts were predominately male [ranging from 22.1%
(PD) to 45.2% (AD/MCI) female], whereas the BEAM healthy
control cohort was predominately female (75%). These sex
differences between ONDRI ND cohorts and BEAM healthy
controls may reflect differences in subject recruitment protocols,
as the ONDRI protocol required participants to have a partner
who knew them well during assessment, and that may have
influenced sample demographics (16, 25). The participation of
a knowledgeable study-partner is critical to dementia-related
research to help manage study logistics (i.e., scheduling study
visits, and transportation) and as informants (26). In the ONDRI
study, the majority of participants had a spousal study partner
and those with spousal study partners were more often male
(25). Indeed, as females generally outlive males, this requirement
may have resulted in biases toward recruitment of males with
surviving female partners within the ONDRI study.
Table 3 also shows the QIDS-SR and GAD-7 scores across
cohorts. ANOVA revealed a significant difference in total QIDSSR score across cohorts [F (7,887) = 261.99, p < 0.01]. As expected,
the MDD cohort had significantly higher QIDS-SR scores (14.92
± 3.76) than the CAN-BIND healthy controls (2.27 ± 1.94) and
all ONDRI ND cohorts (3.93 ± 3.12 to 6.28 ± 3.70) (all p < 0.05).
QIDS-SR scores for the ONDRI cohorts were significantly higher
than BEAM healthy controls (3.04 ± 2.11) for ALS (6.28 ± 3.70),
FTD (5.36 ± 4.07), and PD (5.61 ± 3.28) (all p < 0.05), but not for
AD/MCI (3.93 ± 3.12, p = 0.77) and CVD (4.27 ± 3.11, p = 0.33).
Frontiers in Psychiatry | www.frontiersin.org

DISCUSSION
The Ontario Brain Institute supports multidisciplinary
collaborative Research Networks from across the province
of Ontario and beyond, focusing on various brain conditions.
These programs have generated large volumes of data that
are integrated within the Brain-CODE platform to support
scientific inquiry and analytics across multiple brain diseases
and modalities, including clinical, imaging and molecular
data (1). By providing access to participant-level data across
different disorders, new hypotheses about brain disease and
underlying causes will be generated, and ultimately promote
new discoveries to improve patient care. To help achieve
these goals, the establishment of demographic and clinical
CDEs within Brain-CODE is a critical step toward enabling
consistency in data collection and optimizing the ability of
investigators to analyze pooled participant-level data across
brain disorders. Furthermore, the Brain-CODE CDEs provide
a framework to facilitate collaborations across disciplines and
increase our understanding symptom expression across diseases
and comorbidity.
Adopting a set of standardized assessments across different
disease areas to facilitate sharing of participant-level data is a
challenging endeavor that must consider the need and goals of
individual research programs, since each program must select
the disease-specific measures that are most relevant. As a matter
of good scientific research practice, the measurements selected
should be scientifically valid and justified to support specified
aims. The selection of CDEs, therefore, should consider the
5
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FIGURE 1 | Percentage of participants reporting no (total score ≤ 5), mild (total score = 6–10), moderate (total score = 11–15), severe (total score = 16–20), and very
severe (total score ≥ 21) symptoms of depression in the QIDS-SR across the cohorts.

feasibility, utility, and acceptability of outcome measures that
will benefit from buy-in and cooperation from stakeholders
(6), including engagement of representative researchers through
participation in workshops and agreement on a set of common
assessment and standards. In developing the present set of core
CDEs, Delphi consensus-based methodology was used to inform
and engage stakeholders, gain their input and opinion, and
arrive at an agreement. By including open-ended questions and
comments, suggestions and opinions were not restricted to the
predefined variables, thus allowing for broadening of opinion and
consideration of program-specific needs and challenges.
A key consideration was harmonizing the Brain-CODE CDEs
with those of other large, centralized data repositories and CDE
initiatives, as this would facilitate sharing of data among the
larger research community to allow comparison of the results
from one study with another. One example is the United States
National Institute of Neurological Disorders and Stroke (NINDS)
CDE initiative, which is developing CDEs for NINDS-supported
clinical neuroscience research (27). This CDE initiative includes
many disease areas that are in common with Brain-CODE,
including epilepsy (28), traumatic brain injury (29) and
neurodegenerative diseases (27). The Clinical Data Interchange
Standards Consortium (CDISC) also provide data standards
that should be considered for CDEs, including alignment with
relevant Clinical Data Acquisition Standards Harmonization
(CDASH)-recommended standards and guidelines for recording
of demographic information (30). Indeed, alignment with
existing standards should be an important consideration when
designing a study to support collaborative research and data
sharing, as described in the Guidelines for Data Acquisition,
Quality and Curation for Observational Research Designs
Frontiers in Psychiatry | www.frontiersin.org

(DAQCORD) (31). However, it is important to recognize that
although prospective standardization with existing, relevant
databases is ideal to facilitate data synthesis, implementing
common data collection standards with all relevant initiatives,
particularly established studies and legacy data, is clearly not
possible. Thus, to permit established studies or existing data to
be sufficiently comparable, retrospective harmonization will also
be required to define a set of core variables, including establishing
conventions and equivalencies of data dictionary terms (32).
Neuropsychiatric symptoms are prevalent in neurological
disorders, with rates varying anywhere from 0 to 90%, depending
on the assessments used, patient samples and type of disease
(33–35). Although prevalence rates across neurological disorders
are difficult to ascertain as different outcome measures and
criteria are often used, studies generally show prevalence rates
of depression and anxiety that are higher than in the general
population and negatively impact well-being and progression
of disease (33–35). In the present analysis of participant-level
data pooled across different studies and using standardized
outcome measures, depression scores (QIDS-SR) were found to
be higher in ALS, FTD, and PD cohorts, but not AD/MCI and
CVD, as compared to age-matched controls (see Table 3). The
mean QIDS-SR total scores for the ALS, FTD, and PD cohorts
indicated overall “mild” levels of depression, as compared to the
“moderate” levels observed in the MDD cohort (see Figure 1).
No differences, however, were noted in GAD-7 scores in any of
the ONDRI ND cohorts as compared to age-matched controls.
As part of the ONDRI protocol, individuals with “unstable
psychiatric illness defined as psychosis (hallucinations or
delusions), lifelong history of major depression, or untreated
late-onset major depression within 90 days of the screening
6
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visit” were excluded from the study (16). As a result, individuals
with more severe psychiatric symptoms or a clinical diagnosis of
MDD were excluded from the ONDRI study. However, although
the relatively low levels of depressive symptoms and absence of
anxiety-related symptoms may in part be explained by ONDRI
study selection bias, other factors may also be involved, including
adaptive psychosocial adjustment and coping strategies (36, 37).
This is consistent with the “disability paradox” in which persons
with neurological disorders (and other chronic illnesses) adapt
to their disabilities and report better well-being and quality of life
than would be expected from the general population (36). Studies
are currently underway using the Brain-CODE CDEs to assess
psychosocial determinants of quality of life across disorders.
One of the key objectives of the CAN-BIND and ONDRI
programs is the discovery biomarkers (imaging and ‘omics)
to track disease and treatment response (16, 19). The present
study demonstrates that some symptoms are shared across
disorders, and within disorders, individual symptom profiles
and phenotypes vary. Indeed, there are approximately half a
million symptom profiles that meet criteria for diagnosis of
MDD (38). This heterogeneity presents a challenge to traditional
biomarker and drug discovery research that is based on the
binary classifications of diseases, such as DSM diagnosis; and
given the wide range of phenotypes within diseases, this “topdown” approach to biomarker discover is imprecise at best.
There may be advantages, therefore, to also incorporate a
“bottom-up” strategy to identify relevant clinical phenotypes
and associated biomarkers that will refine our understand of
the pathophysiology underlying disease and ultimately develop
personalized treatment approaches (38, 39).
It is important that CDEs demonstrate good construct
validity across the diverse populations supported by BrainCODE. Although the clinical CDEs were selected in part
because they are widely used, including in some of the disease
areas currently supported in Brain-CODE, the validity of
these outcome assessments across these diverse populations
cannot be fully appreciated until appropriate validation is
performed. In the present study, the GAD-7 showed good
internal consistency across all cohorts, with Cronbach’s alpha of
0.83 or greater and generally acceptable item-total correlations
(see Table 3). By contrast, Cronbach’s alphas for the QIDS-SR
were generally lower (0.68–0.74), with item-total correlations
identifying some items with poor discrimination (see Table 3).
As psychiatric symptoms often overlap with symptoms observed
in neurological disease, it is possible that some of the symptom
assessed by the QIDS-SR and GAD-7 may be confounded with
neurological disease-related symptoms (i.e., sleep, concentration
and psychomotor). As validation relates not only to the
instrument itself, but also how it is being used, it will be
important that the measurement properties of these scales are
evaluated across disease groups. These studies are currently
underway, including the application of item response and Rasch
measurement theory to evaluate scale performance (40).

currently stored in the Brain-CODE Neuroinformatics Platform
(https://www.braincode.ca/) managed by the Ontario Brain
Institute. Requests to access these datasets should be directed to
the Ontario Brain Institute at info@braininstitute.ca.
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